SS-31 vs Survodutide (BI 456906)
Updated November 4, 2026 · Reviewed by the PeptidesDB Editorial team
A data-driven comparison of SS-31 and Survodutide (BI 456906) (also searched as Survodutide (BI 456906) vs SS-31) — effect profiles, evidence, side effects, and which suits weight loss, muscle, or healing goals.
Verdict
SS-31 centers on healing, while Survodutide (BI 456906) leans toward metabolic. On indexed research, SS-31 is ahead (SS-31: 37 studies, Human evidence; Survodutide (BI 456906): 30, Human clinical). Choose by goal — and read the primary studies. This is research information, not medical advice.
Key takeaways
- •SS-31 is strongest for healing; Survodutide (BI 456906) for metabolic.
- •Evidence: SS-31 Human evidence (37 studies) vs Survodutide (BI 456906) Human clinical (30).
- •Both are research-use compounds — not FDA-approved.
Effect profiles, overlaid
At a glance
Mitochondrial protection | Heart and neuro health
Dual Agonist | Obesity and metabolic disorders
SS-31 vs Survodutide (BI 456906): side-by-side
| Metric | SS-31 | Survodutide (BI 456906) |
|---|---|---|
| Class | Metabolic | Metabolic |
| Regulatory status | Research use only | Research use only |
| Evidence grade | Human evidence | Human clinical |
| Studies indexed | 37 | 30 |
| Research level | Preclinical | Well Studied |
| Strongest effect | Healing & recovery | Metabolic & appetite |
| Healing & recovery | 4.0▲ | 1.0 |
| Muscle & body comp | 2.0▲ | 1.0 |
| Metabolic & appetite | 3.0 | 5.0▲ |
| Neuro & mood | 4.0▲ | 1.0 |
| Sleep & circadian | 1.0▲ | 1.0▲ |
| Inflammation & immune | 3.0▲ | 2.0 |
| Skin & aesthetics | 1.0 | 3.0▲ |
▲ marks the higher AI-assigned effect score (0–5, describing where the literature concentrates — not clinical efficacy).
Mechanism & pharmacokinetics
| Property | SS-31 | Survodutide (BI 456906) |
|---|---|---|
| Mechanism | Cardiolipin binding to stabilize mitochondrial membrane | GLP-1/glucagon receptor agonist |
| Route | Subcutaneous injection | Subcutaneous injection |
Established pharmacology — curated for well-characterized compounds and AI-summarized otherwise. A blank (—) means no reliable single value is published (half-life figures for some peptides genuinely disagree across sources). Verify against primary sources such as FDA labels and ClinicalTrials.gov.
What is SS-31?
SS-31, also known as Elamipretide, is a peptide that has garnered attention for its potential role in mitochondrial protection and its implications in various health conditions, particularly those involving oxidative stress and mitochondrial dysfunction.
Full SS-31 profile, mechanism & studies →What is Survodutide (BI 456906)?
Survodutide (BI 456906) is an investigational dual agonist that targets both glucagon-like peptide-1 (GLP-1) and glucagon receptors. This peptide is primarily being studied for its potential in treating obesity and metabolic dysfunction-associated steatotic liver disease (MASLD). The dual action of Survodutide is designed to enhance weight loss while also improving glycemic control, which is particularly relevant for individuals with type 2 diabetes and related metabolic disorders.
Full Survodutide (BI 456906) profile, mechanism & studies →Which is better for your goal?
| Goal | Better fit | Why |
|---|---|---|
| Healing | SS-31 | 4.0/5 effect signal |
| Muscle | SS-31 | 2.0/5 effect signal |
| Metabolic | Survodutide (BI 456906) | 5.0/5 effect signal |
| Neuro | SS-31 | 4.0/5 effect signal |
| Sleep | Even | Both ~1.0/5 |
| Inflammation | SS-31 | 3.0/5 effect signal |
| Skin | Survodutide (BI 456906) | 3.0/5 effect signal |
Fit reflects community-perceived effect profiles — not head-to-head trials. Read each peptide's studies before deciding.
Can you stack SS-31 and Survodutide (BI 456906)?
People sometimes combine peptides that target different pathways, but there is little controlled research on this specific pairing and the interactions aren't well characterized. Because neither compound is FDA-approved, we don't publish stacking or dosing protocols here. Any combination should be discussed with a qualified clinician.
SS-31 vs Survodutide (BI 456906): side effects
No community-reported effects logged yet.
No community-reported effects logged yet.
Anonymous community reports (count = number of reports), not clinical incidence rates.
What the research says
SS-31 has 37 approved studies indexed (Human evidence), and Survodutide (BI 456906) has 30 (Human clinical). The Librarian re-checks PubMed, Europe PMC and ClinicalTrials daily, so these counts move. Open each profile to read the summaries and sources.
Frequently asked questions
Is SS-31 or Survodutide (BI 456906) better?
It depends on your goal. SS-31 is strongest for healing; Survodutide (BI 456906) for metabolic. SS-31 has more indexed studies (37). See the goal-by-goal breakdown above.
Is SS-31 or Survodutide (BI 456906) better for weight loss?
Survodutide (BI 456906) shows the stronger metabolic & appetite profile (5.0/5) in the AI-assigned effect profile — though weight-loss outcomes depend on the individual and the evidence base.
Is SS-31 or Survodutide (BI 456906) better for muscle?
SS-31 leads on the muscle & body-composition axis (2.0/5).
Which has more research, SS-31 or Survodutide (BI 456906)?
SS-31 has 37 approved studies indexed (Human evidence); Survodutide (BI 456906) has 30 (Human clinical). Higher counts mean more to read, not proven superiority.
Can you stack SS-31 and Survodutide (BI 456906)?
Some users combine peptides, but there's little controlled data on this specific pairing, and interactions aren't well characterized. We don't publish stacking protocols for compounds that aren't FDA-approved. Discuss any combination with a qualified clinician.
What are the side effects of SS-31 vs Survodutide (BI 456906)?
SS-31: no community-reported effects logged yet. Survodutide (BI 456906): none logged yet. These are anonymous reports, not incidence rates — see each profile.
Is SS-31 or Survodutide (BI 456906) FDA-approved?
SS-31 is a research-use compound and is not FDA-approved. Survodutide (BI 456906) is not FDA-approved. Research-use status is not a legal clearance to compound or use in humans.
Is Survodutide (BI 456906) better than SS-31?
For metabolic, Survodutide (BI 456906) has the edge; for healing, SS-31 does. Neither is universally "better" — it's goal-dependent, and both should be weighed against their evidence base above.
Comparing related peptides
Regulatory & legal status
SS-31 and Survodutide (BI 456906) are research-use compounds and are not FDA-approved for human use. FDA approval and compounding rules for peptides change frequently, and research-use status is not a legal clearance for human use. The FDA does not review compounded drugs for safety, effectiveness, or quality. Verify current status with primary sources before acting. Last reviewed November 4, 2026.